Amendment to Annual Report (SEC Filing - 10-K/A)

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

Amendment No. 1

to

FORM 10-K/A

​

​	​
☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

For the fiscal year ended December 31, 2020

​

or

​	​
☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

For the transition period from to

​

Commission File Number: 001-39169

​

Kiromic BioPharma, Inc.

(Exact name of registrant as specified in its charter)

​

​	​	​
​	​	​
Delaware		46-4762913
(State or other jurisdiction of incorporation or organization)	​	(I.R.S. Employer Identification Number)

​

​	​	​
7707 Fannin Street, Suite 140, Houston, TX		77054
(Address of Principal Executive Offices)	​	Zip Code

​

​

(832) 968-4888

(Registrant's telephone number)

​

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​	​	​
​	​	​	​	​
Title of Each Class		Trading symbol		Name of Exchange on which registered
Common Shares, par value $0.001 per share	​	KRBP	​	The Nasdaq Stock Market

​

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒No ☐

​

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒No ☐

​

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 232.405 of this chapter) is not contained herein, and will not be contained, to the best of Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of 'large accelerated filer,' 'accelerated filer,' 'smaller reporting company,' and 'emerging growth company' in Rule 12b-2 of the Exchange Act.

​

​ ​ ​ ​ ​	​	​	​	​
​	Large Accelerated Filer ☐	​	Accelerated Filer ☐	​
​	Non-accelerated Filer ☒	​	Smaller Reporting Company ☒	​
​	​	​	Emerging Growth Company ☒	​

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

​

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐No ☒

As of March 31, 2021, there were 7,332,999 of the registrant's ordinary shares outstanding.

​

Table of Contents

EXPLANATORY NOTE

​

This Amendment No. 1 (the 'Amendment') to the Annual Report on Form 10-K/A of Kiromic BioPharma, Inc. (the 'Company') for the fiscal year ended December 31, 2020, originally filed with the Securities and Exchange Commission (the 'SEC') on March 31, 2021 (the 'Original Filing'), is being filed solely to include a fully executed signature page to Form 10-K inadvertently omitted by the Company when originally filed. This Amendment contains only the cover page, this explanatory note, the signature page and the revised certifications.

Except for the foregoing, this Amendment does not alter or update any information contained in the Original Filing. The Original Filing continues to speak as of the date of the Original Filing, and the Company has not updated the disclosures contained therein to reflect any events that have occurred as of a date subsequent to the date of the Original Filing. Accordingly, this Amendment should be read in conjunction with the Original Filing, and the Company's filings made with the SEC subsequent to the filing of the Original Filing.

​

PART IV

​

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

​

	(2)	Financial Statement Schedules:

​

All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.

(3)	Exhibits.

​

EXHIBIT INDEX

	​
Exhibit No.	​	Description of Exhibit
3.1	​	Fourth Amended and Restated Certificate of Incorporation of Kiromic BioPharma, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on October 21, 2020)
3.2	​	Second Amended and Restated Bylaws of Kiromic BioPharma, Inc. (incorporated by reference to Exhibit 3.5 to the Company's Registration Statement on Form S-1/A filed on October 6, 2020)
4.1**	​	Description of Securities
10.1†	​	Employment Agreement between Kiromic BioPharma, Inc. and Tony Tontat (incorporated by reference to Exhibit 10.3 to the Company's Registration Statement on Form S-1/A filed on October 6, 2020)
10.2#	​	License Agreement, dated December 1, 2016, between Mercer University and Kiromic BioPharma, Inc. (incorporated by reference to Exhibit 10.10 to the Company's Registration Statement on Form S-1/A filed on October 6, 2020)
10.3#	​	License Agreement, dated September 14, 2018, between CGA 369 Intellectual Holdings, Inc. and Kiromic BioPharma, Inc. (incorporated by reference to Exhibit 10.11 to the Company's Registration Statement on Form S-1/A filed on October 6, 2020)

​

Table of Contents

10.4#	​	Amendment to License Agreement, dated October 16, 2019, between CGA 369 Intellectual Holdings, Inc. and Kiromic BioPharma, Inc. (incorporated by reference to Exhibit 10.12 to the Company's Registration Statement on Form S-1/A filed on October 6, 2020)
10.5#	​	Collaboration Agreement, dated February 6, 2020, between University of Texas MD Anderson Cancer Center and Kiromic BioPharma, Inc. (incorporated by reference to Exhibit 10.14 to the Company's Registration Statement on Form S-1/A filed on October 6, 2020)
10.6†	​	Employment Agreement dated January 1, 2020 between Kiromic BioPharma, Inc and Scott Dahlbeck (incorporated by reference to Exhibit 10.19 to the Company's Registration Statement on Form S-1/A filed on October 6, 2020)
10.7†	​	Employment Agreement between Kiromic BioPharma, Inc. and Gianluca Rotino (incorporated by reference to Exhibit 10.20 to the Company's Registration Statement on Form S-1/A filed on October 6, 2020)
10.8†	​	Employment Agreement between Kiromic BioPharma, Inc. and Maurizio Chiriva Internati (incorporated by reference to Exhibit 10.21 to the Company's Registration Statement on Form S-1/A filed on October 6, 2020)
10.9†	​	Kiromic, Inc. 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.22 to the Company's Registration Statement on Form S-1/A filed on October 6, 2020)
10.10#	​	Joint venture agreement, dated 4.06.2020, between Molipharma S.R.L. and Kiromic BioPharma, Inc. (incorporated by reference to Exhibit 10.23 to the Company's Registration Statement on Form S-1/A filed on October 6, 2020)
10.11†	​	Form of Director Services Agreement between Kiromic BioPharma, Inc. and all independent directors (incorporated by reference to Exhibit 10.24 to the Company's Registration Statement on Form S-1/A filed on October 6, 2020)
10.12†	​	Amended and Restated License Agreement by and between the Company and Longwood University, dated as of November 30, 2020 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on January 29, 2021)
10.13	​	Strategic Alliance Agreement by and between the Company and Leon Office (H.K.) Ltd, effective as of January 28, 2021 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on February 12, 2021)
21.1**	​	List of Subsidiaries
23.1**	​	Consent of Deloitte & Touche LLP, independent registered public accounting firm
31.1*		Certifications of Principal Executive Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*	​	Certifications of Principal Financial Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**		Certifications of Principal Executive Officer furnished pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**	​	Certifications of Principal Financial Officer furnished pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS**		Inline XBRL Instance Document
101.SCH**		Inline XBRL Taxonomy Extension Schema Document
101.CAL**		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**		Inline XBRL Taxonomy Extension Definition Linkbase Document

​

Table of Contents

101.LAB**		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE**		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	​	Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

_

*Filed herewith

** Previously filed

† Executive Compensation Plan or Agreement

​

# Portions of this exhibit (indicated by asterisks) have been redacted in compliance with Regulation S-K Item 601(b)(10)(iv).

​

​

​

​

​

​

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

​	​	​ Chief Executive Officer and Director (Principal Executive Officer) ​
​	Kiromic BioPharma, Inc.
​	​
Dated: June 1, 2021	By: ​	/s/ Maurizio Chiriva-Internati Maurizio Chiriva-Internati Chief Executive Officer and Director (Principal Executive Officer)
​	​	​
​	​	​
Dated: June 1, 2021	By: ​	/s/ Tony Tontat Tony Tontat Chief Financial Officer (Principal Financial and Accounting Officer)

​

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

​	​	​	​	​	​	​	​	​
​	Signature	​	​	Title	​	​	Date	​
​	​	​
/s/ Maurizio Chiriva-Internati Maurizio Chiriva-Internati	Chief Executive Officer (Principal Executive Officer)	June 1, 2021
​	​	​
/s/ Tony Tontat Tony Tontat	Chief Financial Officer (Principal Financial and Accounting Officer)	June 1, 2021
​	​	​
/s/ Gianluca Rotino Gianluca Rotino	Director	June 1, 2021
​	​	​
/s/ Pietro Bersani Pietro Bersani	Director	June 1, 2021
​	​	​
/s/ Americo Cicchetti Americo Cicchetti	Director	June 1, 2021
​	​	​
/s/ Jerry Schneider Jerry Schneider	Director	June 1, 2021
​	​	​
/s/ Michael Nagel Michael Nagel	Director	June 1, 2021

​

​